Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Intangibles (2020 - 2025)

Historic Intangibles for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $17.7 million.

  • Cytek Biosciences' Intangibles fell 1374.19% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year decrease of 1374.19%. This contributed to the annual value of $20.1 million for FY2024, which is 1280.54% down from last year.
  • As of Q3 2025, Cytek Biosciences' Intangibles stood at $17.7 million, which was down 1374.19% from $18.6 million recorded in Q2 2025.
  • Cytek Biosciences' Intangibles' 5-year high stood at $24.7 million during Q1 2023, with a 5-year trough of $333000.0 in Q2 2021.
  • Its 5-year average for Intangibles is $14.3 million, with a median of $19.0 million in 2025.
  • Per our database at Business Quant, Cytek Biosciences' Intangibles skyrocketed by 162956.2% in 2021 and then plummeted by 1564.3% in 2024.
  • Cytek Biosciences' Intangibles (Quarter) stood at $4.7 million in 2021, then dropped by 8.61% to $4.3 million in 2022, then skyrocketed by 432.99% to $23.1 million in 2023, then fell by 12.81% to $20.1 million in 2024, then dropped by 12.18% to $17.7 million in 2025.
  • Its Intangibles was $17.7 million in Q3 2025, compared to $18.6 million in Q2 2025 and $19.4 million in Q1 2025.